165 related articles for article (PubMed ID: 36975020)
21. Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors.
Niu P; Tao Y; Lin G; Xu H; Meng Q; Yang K; Huang W; Song M; Ding K; Ma D; Fan M
J Med Chem; 2024 Apr; 67(8):6099-6118. PubMed ID: 38586950
[TBL] [Abstract][Full Text] [Related]
22. Dominant-negative mutants reveal a role for the Cdk7 kinase at the mid-blastula transition in Drosophila embryos.
Leclerc V; Raisin S; Léopold P
EMBO J; 2000 Apr; 19(7):1567-75. PubMed ID: 10747025
[TBL] [Abstract][Full Text] [Related]
23. Regulation of CAK kinase activity by p53.
Schneider E; Montenarh M; Wagner P
Oncogene; 1998 Nov; 17(21):2733-41. PubMed ID: 9840937
[TBL] [Abstract][Full Text] [Related]
24. TGF-β/activin signaling promotes CDK7 inhibitor resistance in triple-negative breast cancer cells through upregulation of multidrug transporters.
Webb BM; Bryson BL; Williams-Medina E; Bobbitt JR; Seachrist DD; Anstine LJ; Keri RA
J Biol Chem; 2021 Oct; 297(4):101162. PubMed ID: 34481843
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
Song X; Fang C; Dai Y; Sun Y; Qiu C; Lin X; Xu R
Br J Cancer; 2024 May; 130(8):1239-1248. PubMed ID: 38355840
[TBL] [Abstract][Full Text] [Related]
26. A patent and literature review of CDK12 inhibitors.
Tang R; Liu J; Li S; Zhang J; Yu C; Liu H; Chen F; Lv L; Zhang Q; Yuan K; Shao H
Expert Opin Ther Pat; 2022 Oct; 32(10):1055-1065. PubMed ID: 36120913
[TBL] [Abstract][Full Text] [Related]
27. Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase.
Fisher RP; Jin P; Chamberlin HM; Morgan DO
Cell; 1995 Oct; 83(1):47-57. PubMed ID: 7553872
[TBL] [Abstract][Full Text] [Related]
28. Meiotic expression of the cyclin H/Cdk7 complex in male germ cells of the mouse.
Kim JM; McGaughy JT; Bogle RK; Ravnik SE
Biol Reprod; 2001 May; 64(5):1400-8. PubMed ID: 11319144
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in the development of cyclin-dependent kinase 7 inhibitors.
Teng Y; Lu K; Zhang Q; Zhao L; Huang Y; Ingarra AM; Galons H; Li T; Cui S; Yu P; Oumata N
Eur J Med Chem; 2019 Dec; 183():111641. PubMed ID: 31514062
[TBL] [Abstract][Full Text] [Related]
30. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Bisteau X; Paternot S; Colleoni B; Ecker K; Coulonval K; De Groote P; Declercq W; Hengst L; Roger PP
PLoS Genet; 2013 May; 9(5):e1003546. PubMed ID: 23737759
[TBL] [Abstract][Full Text] [Related]
31. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
[TBL] [Abstract][Full Text] [Related]
32. Molecular cloning of CDK7-associated human MAT1, a cyclin-dependent kinase-activating kinase (CAK) assembly factor.
Yee A; Nichols MA; Wu L; Hall FL; Kobayashi R; Xiong Y
Cancer Res; 1995 Dec; 55(24):6058-62. PubMed ID: 8521393
[TBL] [Abstract][Full Text] [Related]
33. Modulation of TFIIH-associated kinase activity by complex formation and its relationship with CTD phosphorylation of RNA polymerase II.
Watanabe Y; Fujimoto H; Watanabe T; Maekawa T; Masutani C; Hanaoka F; Ohkuma Y
Genes Cells; 2000 May; 5(5):407-23. PubMed ID: 10886368
[TBL] [Abstract][Full Text] [Related]
34. Xenopus phospho-CDK7/cyclin H expressed in baculoviral-infected insect cells.
Lawrie AM; Tito P; Hernandez H; Brown NR; Robinson CV; Endicott JA; Noble ME; Johnson LN
Protein Expr Purif; 2001 Nov; 23(2):252-60. PubMed ID: 11676600
[TBL] [Abstract][Full Text] [Related]
35. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H.
Higashi H; Suzuki-Takahashi I; Saitoh S; Segawa K; Taya Y; Okuyama A; Nishimura S; Kitagawa M
Eur J Biochem; 1996 Apr; 237(2):460-7. PubMed ID: 8647086
[TBL] [Abstract][Full Text] [Related]
37. Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation.
Nishiwaki E; Turner SL; Harju S; Miyazaki S; Kashiwagi M; Koh J; Serizawa H
Mol Cell Biol; 2000 Oct; 20(20):7726-34. PubMed ID: 11003668
[TBL] [Abstract][Full Text] [Related]
38. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase.
Fisher RP; Morgan DO
Cell; 1994 Aug; 78(4):713-24. PubMed ID: 8069918
[TBL] [Abstract][Full Text] [Related]
39. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.
Olson CM; Liang Y; Leggett A; Park WD; Li L; Mills CE; Elsarrag SZ; Ficarro SB; Zhang T; Düster R; Geyer M; Sim T; Marto JA; Sorger PK; Westover KD; Lin CY; Kwiatkowski N; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):792-803.e10. PubMed ID: 30905681
[TBL] [Abstract][Full Text] [Related]
40. Interactions of Cdk7 and Kin28 with Hint/PKCI-1 and Hnt1 histidine triad proteins.
Korsisaari N; Mäkelä TP
J Biol Chem; 2000 Nov; 275(45):34837-40. PubMed ID: 10958787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
